SCHEMBL5401495

SCHEMBL5401495

Cc1[nH]c(C=O)c(C)c1-c1ccc(C(=O)N2CCOCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
HTT P42858 1/20 0.48
ERN1 O75460 4/20 0.47
PHGDH O43175 1/20 0.47
CHEK1 O14757 1/20 0.45
RIPK1 Q13546 1/20 0.43
AKR1C3 P42330 1/20 0.43
FLT1 P17948 1/20 0.43
KDR P35968 1/20 0.43
BRD4 O60885 1/20 0.43
TAF1 P21675 1/20 0.43
CECR2 Q9BXF3 1/20 0.43
BRD9 Q9H8M2 1/20 0.43
JAK2 O60674 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5406964 0.87 POLB (0.52) HPGDRIPK1BRD4
SCHEMBL5396584 0.86 ERN1 (0.55) HPGDKDM4EALDH1A1ERN1FLT1
SCHEMBL5403365 0.78 TSHR (0.58) HPGDKDM4EALDH1A1HTTERN1
SCHEMBL13195269 0.77 TSHR (0.56) HPGDSMN1; SMN2KDM4EALDH1A1HTT
SCHEMBL5399079 0.76 ALDH1A1 (0.47) HPGDSMN1; SMN2KDM4EALDH1A1ERN1
SCHEMBL21916152 0.76 KDR (0.75) ERN1CHEK1RIPK1FLT1KDR
SCHEMBL17194215 0.73 HPGD (0.63) HPGDSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL10720943 0.72 PHGDH (0.81) HPGDSMN1; SMN2KDM4EALDH1A1MAPT
SCHEMBL21915961 0.72 SENP1 (0.46) SMN1; SMN2ALDH1A1MAPTHTTERN1
SCHEMBL1662915 0.72 PHGDH (0.65) HPGDSMN1; SMN2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-7157577-B2 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. (US) 2007-01-02 US disclosed
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) SUGEN, INC. 2004-12-30 US disclosed
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors SUGEN INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204407-A1 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors DMPK, MAP3K20, PHKG1 HPGD 1305/4885SMN1; SMN2 2489/4885KDM4E 1046/4885
US-20040266843-A1 Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK) CHEK2, CHEK1, ATM HPGD 1183/4885SMN1; SMN2 4218/4885KDM4E 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.